https://cancer.holy-cross.com---https://cancer.holy-cross.com/cancer-clinical-trials
Skip to Content
image description
  • image description
  • image description
  • image description

Cancer Clinical Trials Information at Holy Cross

The Michael and Dianne Bienes Comprehensive Cancer at Holy Cross Hospital in Fort Lauderdale in Broward County (South Florida) offers an extensive panel of research studies, or clinical trials, to those battling breast cancer, colorectal cancer, lung cancer, melanoma (skin cancer), multiple myeloma (cancer of the plasma cells), leukemia (cancer of the blood cells) and other cancers. 

We also offer biomarker-driven trials for which the location of the tumor may not matter. Please scroll to learn more.

Lung – Advanced, Treatment Experienced

D5160L00032

RADIANCE: Resistance and Activating Mutations DIAgnosed Among Non-small Cell Lung Cancer, Community Dwelling, EGFR Mutation Positive Patients.

An open-label, non-randomized, prospective biomarker study to assess analytic concordance and clinical validity between non-invasive testing and tissue testing for EGFR T790M mutation detection in patients with non-small cell lung cancer. 

Contact: Kathy McTague, 954-267-7718 or kathleen.mctague@holy-cross.com

Biomarker-driven Trials (location of the cancer may not matter)

STARTRK-2

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements.

For more information, contact Study Coordinator Mariana Lykoudis at 954-267-7792 or mariana.lykoudis@holy-cross.com

Brain Cancer – Glioblastoma

M13-813 Intellance 1 Study

A Randomized, Placebo Controlled Phase 2b/3 Study of ABT-414 with Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects with Newly Diagnosed Glioblastoma (GBM) with Epidermal Growth Factor Receptor (EGFR) Amplification.

Contact: Mariana Lykoudis, 954-267-7792 or mariana.lykoudis@holy-cross.com

Breast - Androgen Receptor-Positive Triple Negative Breast Cancer

G200901

A Phase 2 Open Label, Multi-Center, Multinational Study Investigating The Efficacy and Safety Of GTx-024 On Advanced, Androgen Receptor-Positive Triple Negative Breast Cancer (AR+TNBC).

For more information, contact Study Coordinator Eileen Georgi at 954-267-7748 or eileen.georgi@holy-cross.com

Breast Registry

CALLER Registry

Collaborative Attempt to Lower Lumpectomy Re-excision Rates. Contact: Dr. Joseph Casey or Eileen Georgi, 954-267-7748 or Eileen.georgi@holy-cross.com

Breast Registry

Nipple Sparing Registry

ASBrS Nipple Sparing Mastectomy Registry.

For more information, contact Study Coordinator Eileen Georgi at 954-267-7748 or eileen.georgi@holy-cross.com

Breast – Post-menopausal women with metastatic or advanced breast cancer

C31006

An Open-Label Phase 2 Study of MLN0128 (A TORC1/2 Inhibitor) in Combination With Fulvestrant in Women With ER-Positive/HER2-Negative Advanced or Metastatic Breast Cancer That Has Progressed During or After Aromatase Inhibitor Therapy.

Contact: Eileen Georgi, 954-267-7748 or eileen.georgi@holy-cross.com

Gastric Cancer

HALO-107-101

A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined with Pembrolizumab in Subjects with Selected Hyaluronan-High Solid Tumors.

http://halo101.com/

Contact: Tia Morgan, 954-229-8528 or tia.morgan@holy-cross.com

Genetic Registry

City of Hope Registry

Molecular Genetics Studies of Cancer Patients and Their Relatives.

For more information, contact Eileen Georgi, 954-267-7748 or eileen.georgi@holy-cross.com
 

Head and Neck Cancer, Early Stage

EMR100036-002

An Open Label, Phase Ia/Ib Trial of the DNA-PK Inhibitor MSC2490484A in Combination with Radiotherapy in Patients with Advanced Solid Tumors.

Contact: Eileen Georgi, 954-267-7748 or eileen.georgi@holy-cross.com

Iron Deficiency Anemia

IDA-03

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose in subjects with iron deficiency anaemia who are intolerant or unresponsive to oral iron therapy or in whom the haemoglobin measurement in Investigators' opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Contact: Tia Morgan, 954-229-8528 or tia.morgan@holy-cross.com

Lung – Advanced, Chemotherapy Naive

INI-001

Prospective observational multicenter study to evaluate the performance of Inivata liquid biopsy analysis compared with standard tissue biopsy analysis for detection of genomic alterations in patients with advanced non-small cell lung cancer.

For more information, contact Study Coordinator Tia Morgan at 954-229-8528 or tia.morgan@holy-cross.com

 

Lung – Advanced, Treatment Experienced

MS200095-0022

A Phase 2 single-arm trial to investigate tepotinib in Stage IIIB/IV adenocarcinoma of the lung with MET exon 14 (METex14) skipping alterations after failure 

of at least one platinum-containing chemotherapy.

For more information, contact Study Coordinator Mariana Lykoudis at 954-267-7792 or mariana.lykoudis@holy-cross.com

Lung – Advanced, Treatment Experienced

Geometry-1

A phase II study to evaluate antitumor activity of oral cMET inhibitor INC280 in adult patients with EGFR wild-type, advanced non-small cell lung cancer 

(NSCLC) after one or two prior lines of systemic therapy for advanced/metastatic disease as measured by overall response rate (ORR). The study will 

also evaluate safety and pharmacokinetics of INC280.

For more information, contact Study Coordinator Mariana Lykoudis at 954-267-7792 or mariana.lykoudis@holy-cross.com

Lung – Advanced, Treatment Naïve or Experienced

HALO-107-101

A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined with Pembrolizumab in Subjects with Selected Hyaluronan-High Solid Tumors.

http://halo101.com/

Contact: Tia Morgan, 954-229-8528 or tia.morgan@holy-cross.com

Pages

Three Women Photo

Cancer risk assessment, screening and prevention programs are vital to educating people about reducing their chances of developing cancer and assessing the need for intervention. Under the direction of our genetic nurse counselor and the Bienes Cancer Center physicians, our Cancer Risk and Prevention Program is for anyone with cancer or a family history of cancer. The vast majority of participants are women who have or have had breast or ovarian cancer, or are at high risk of developing these two cancers. Click to learn more about Genetic Counseling.

Cancer Resources

More Cancer Resources

®2005-2011 WebMD, LLC. All rights reserved.

WebMD does not provide medical advice, diagnosis or treatment.

See additional information.

Directions

image description